508 related articles for article (PubMed ID: 17032413)
21. Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.
Rodríguez-Torres M; Ríos-Bedoya CF; Ortiz-Lasanta G; Purcell-Arevalo D; Marxuach-Cuétara A; Jiménez-Rivera J
J Med Virol; 2008 Sep; 80(9):1576-80. PubMed ID: 18649339
[TBL] [Abstract][Full Text] [Related]
22. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
Hung CH; Kuo FY; Wang JH; Lu SN; Hu TH; Chen CH; Lee CM; Eng HL
Antivir Ther; 2006; 11(4):483-9. PubMed ID: 16856622
[TBL] [Abstract][Full Text] [Related]
23. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
Alsaran K; Sabry A; Shaheen N
Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
[TBL] [Abstract][Full Text] [Related]
24. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
26. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1.
Petta S; Amato M; Cabibi D; Cammà C; Di Marco V; Giordano C; Galluzzo A; Craxì A
Hepatology; 2010 Nov; 52(5):1543-52. PubMed ID: 20799355
[TBL] [Abstract][Full Text] [Related]
27. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C.
Coban S; Idilman R; Erden E; Tüzün A
Hepatogastroenterology; 2011; 58(109):1301-6. PubMed ID: 21937399
[TBL] [Abstract][Full Text] [Related]
28. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.
Murdaca G; Contini P; Cagnati P; Marenco S; Pieri G; Lantieri F; Picciotto A; Puppo F
Clin Exp Med; 2017 Feb; 17(1):93-100. PubMed ID: 26567007
[TBL] [Abstract][Full Text] [Related]
29. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
[TBL] [Abstract][Full Text] [Related]
30. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
Cross TJ; Quaglia A; Nolan J; Hughes S; Harrison PM
J Med Virol; 2010 May; 82(6):958-64. PubMed ID: 20419809
[TBL] [Abstract][Full Text] [Related]
31. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
32. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
33. Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naïve chronic hepatitis C Patients infected with genotypes 1 and 3.
Selic Kurincic T; Lesnicar G; Poljak M; Meglic Volkar J; Rajter M; Prah J; Baklan Z; Kotar T; Maticic M
Intervirology; 2014; 57(1):23-30. PubMed ID: 24080608
[TBL] [Abstract][Full Text] [Related]
34. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin.
Guidi M; Muratori P; Granito A; Muratori L; Pappas G; Lenzi M; Bianchi FB
Aliment Pharmacol Ther; 2005 Nov; 22(10):943-9. PubMed ID: 16268968
[TBL] [Abstract][Full Text] [Related]
35. Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
Elefsiniotis IS; Pavlidis C; Ketikoglou I; Koutsounas S; Scarmeas N; Pantazis KD; Moulakakis A; Tsianos EV
Eur J Intern Med; 2008 Jun; 19(4):266-70. PubMed ID: 18471675
[TBL] [Abstract][Full Text] [Related]
36. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
Basso M; Giannini EG; Torre F; Blanchi S; Savarino V; Picciotto A
Hepatology; 2009 May; 49(5):1442-8. PubMed ID: 19350657
[TBL] [Abstract][Full Text] [Related]
37. Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.
Parise ER; de Oliveira AC; Conceição RD; Amaral AC; Leite K
Braz J Infect Dis; 2006 Apr; 10(2):78-81. PubMed ID: 16878256
[TBL] [Abstract][Full Text] [Related]
38. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels.
Iwasa M; Hara N; Miyachi H; Tanaka H; Takeo M; Fujita N; Kobayashi Y; Kojima Y; Kaito M; Takei Y
J Viral Hepat; 2009 Oct; 16(10):716-23. PubMed ID: 19302338
[TBL] [Abstract][Full Text] [Related]
39. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
40. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland.
Innes HA; Hutchinson SJ; Allen S; Bhattacharyya D; Bramley P; Carman B; Delahooke TE; Dillon JF; Goldberg DJ; Kennedy N; Mills PR; Morris J; Morris J; Robertson C; Stanley AJ; Hayes P;
Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):646-55. PubMed ID: 22433796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
